Company Filing History:
Years Active: 2023
Title: **Innovator Spotlight: Sunil Mahor**
Introduction
Sunil Mahor, based in Pune, India, is a notable inventor recognized for his significant contribution to the field of vaccine development. With a single patent to his name, he is making strides in the scientific community, particularly focusing on enterovirus inactivation.
Latest Patents
Sunil Mahor holds a patent titled "Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof." This innovative invention focuses on enhanced methods for enterovirus inactivation through the use of formaldehyde in conjunction with tromethamine buffer, which ensures the maximum recovery of D-antigen. An important aspect of his work involves the adsorption of the inactivated poliovirus (sIPV) onto aluminium hydroxide, which allows for the production of significantly dose-reduced sIPV compositions.
Career Highlights
Sunil is associated with the Serum Institute of India Pvt Ltd, a leading biotechnology company known for its extensive range of vaccines. His work primarily revolves around improving vaccine formulations, making them more effective and accessible to populations in need. His innovative approaches contribute to the ongoing efforts to enhance public health through better vaccine technology.
Collaborations
In his journey, Sunil Mahor has collaborated with talented coworkers such as Rajeev Mhalasakant Dhere and Sambhaji Shankar Pisal, who share his passion for innovation in the field of vaccine research and development. Their combined expertise fosters an environment of creativity and scientific advancement, pushing the boundaries of current vaccine methodologies.
Conclusion
Sunil Mahor's dedication to innovation in vaccine development showcases the vital role of inventors in enhancing public health solutions. His patent represents a significant step toward more effective vaccine compositions, thus contributing to the global fight against infectious diseases. As he continues his research with the Serum Institute of India, the potential for further advancements in this field remains promising.